News
The Discovery Stage Partnering Agreements in Biopharma Report Provides Data on Deal Trends Since 2000, Over 1000 Actual Contracts and Real Case Studies
DUBLIN, Ireland-(Business Wire)-September 4, 2008 - Research and Markets (http://www.researchandmarkets.com/research/849824/discovery_stage_pa) has announced the addition of the "Discovery Stage Partnering Agreements in Biopharma" report to their offering.
The Discovery Stage Partnering Agreements in Biopharma report provides a detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement.
The focus of the report is on partnerships for discovery technologies and discovery stage compounds where partners have joined forces to exploit these early stage opportunities. This is the earliest stage of partnering undertaken by commercial entities with the objective of utilizing discovery technologies to identify promising drug candidates.
Key Benefits
Discovery Stage Partnering Agreements in Biopharma provides the reader with the following key benefits:
- In-depth understanding of discovery stage partnering deal trends since 2000
- Analysis of the structure of discovery stage partnering agreements with numerous real life case studies
- Comprehensive access to over 1000 actual discovery stage partnering contracts entered into by the world’s biopharma companies(A)
- Detailed access to actual discovery stage partnering contracts enter into by the leading fifty bigpharma companies(A)
- Insight into the payment and deal terms included in a discovery stage partnering agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
(A) Subject to being published via regulatory requirements of the Securities Exchange Commission.
Report Scope:
Discovery Stage Partnering Agreements in Biopharma is intended to provide the reader with an in-depth understanding of the discovery stage partnering trends and structure of deals entered into by leading biopharma companies worldwide.
Discovery Stage Partnering Agreements in Biopharma includes:
- Trends in discovery stage partnering dealmaking in the biopharma industry since 2000
- Analysis of discovery stage partnering deal structure
- Average payment terms for discovery stage deals
- Case studies of real-life discovery stage partnering deals
- Access to over 1000 discovery stage partnering contract documents
- The leading discovery stage partnering deals by value since 2000
- Most active discovery stage partnering dealmakers since 2000
- The leading discovery stage partnering resources
In Discovery Stage Partnering Agreements in Biopharma, the available contracts are listed by:
- A-Z
- Headline value
- Therapeutic area
- Deal type
Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. The Discovery Stage Partnering Agreements in Biopharma report provides comprehensive access to available contract documents for over 1000 discovery stage partnering deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How do milestone align with clinical stage development phases?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
- Trends in discovery stage dealmaking
- Overview of discovery stage deal structure
- Leading discovery stage deals
- Bigpharma discovery stage partnering agreements
- Discovery partnering agreement directory 2003-early 2008
- Table of Figures
Companies Mentioned:
- AstraZeneca
- Barr Pharmaceuticals
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Chugai
- CSL
- Daiichi Sankyo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- King
- Lundbeck
- Menarini
- Merck & Co
- Merck – Serono KGaA
- Mitsubishi
- Mundipharma
- Novartis AG
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Procter & Gamble
- Ratiopharm
- Roche
- Sanofi-Aventis
- Schering Plough
- Servier
- Shire
- Solvay
- Stada
- Takeda
- Teva
- UCB
- Watson
- Wyeth
For more information visit http://www.researchandmarkets.com/research/849824/discovery_stage_pa
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
